Annual report pursuant to Section 13 and 15(d)

8. Hybrid Debt Instrument (Details Narrative)

v3.8.0.1
8. Hybrid Debt Instrument (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Loss on issuance of hybrid debt instruments $ 0 $ (1,690,784)
Gain (loss) on extinguishment of debt $ 0 (6,394,921)
Initial APA Note [Member] | Pharmsynthez and Kevelt [Member]    
Convertible note face value   3,500,000
Loss on issuance of hybrid debt instruments   (1,600,000)
Gain on change in fair value of hybrid instrument   $ 1,900,000
Hybrid Debt Instrument [Member] | Pharmsynthez [Member]    
Devt converted, shares issued   1,400,000
Debt converted, debt amount   $ 6,500,000
Debt converted, interest converted   200,000
Gain (loss) on extinguishment of debt   (6,200,000)
Additional APA Note [Member] | Pharmsynthez [Member]    
Convertible note face value   $ 500,000
Conversion price   $ 4.95
Warrants issued   50,506
CEO Note [Member] | M. Scott Maguire [Member]    
Convertible note face value   $ 369,958
Warrants issued   37,369
Interest expense   $ 13,176
Further Notes [Member] | Note 1 [Member]    
Convertible note face value   $ 178,000
Conversion price   $ 4.00
Further Notes [Member] | Note 2 [Member]    
Convertible note face value   $ 322,000
Conversion price   $ 4.00
Period Notes [Member]    
Gain on change in fair value of hybrid instrument   $ (100,000)
All Notes [Member]    
Interest expense   $ 700,000